Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matria Healthcare (MATR) -- Ignore unavailable to you. Want to Upgrade?

To: GREATMOOD who wrote (160)	11/10/1998 10:38:00 AM
From: GREATMOOD	Read Replies (1) \| Respond to of 220

Matria is in the Right Place at the Right Time........ By 2005, Type 2 Diabetes Patients Will Represent 6% Of The U.S. Adult Population, According To A New DR Report Sharp Increases In Morbidity, Mortality, And Health Care Costs Are Expected... WALTHAM, Mass., Nov. 10 /PRNewswire/ -- Throughout the next decade, we will see a dramatic increase in type 2 diabetes patients, resulting in a compounded need for therapies to treat diabetic complications. The major cause of diabetes-associated morbidity and mortality has been linked to the long-term complications of diabetes rather than the disease itself. Likewise, nearly 80% of the direct costs of diabetes in the United States are due to health care expenditures associated with diabetic complications. Recent revisions in the American Diabetes Association's Standards of Care and Criteria for Diagnosis, along with federal government initiatives such as the Diabetes Quality Improvement Project, the National Diabetes Education Program, and increased Medicare coverage for blood glucose monitors speak to the urgency of this major public health crisis. New Strategies for the Treatment of Diabetes and Its Long-Term Complications, a new DR Report from Decision Resources, studies the mechanisms of diabetes, insulin resistance, and Syndrome X, and how these conditions give rise to visual, renal, neurological, and cardiovascular consequences. Based on a thorough evaluation of current and emerging approaches to treating diabetic complications, we predict the following developments in the seven major pharmaceutical markets through 2005: Retinopathy -- Laser surgery will remain the preferred treatment for proliferative retinopathy and macular edema. Neuropathy -- The seven-country market will be worth $1.7 billion by 2005, driven by a shift from purely symptomatic therapies to drugs which attempt to address the disease itself. Nephropathy -- Due to a lack of new agents and downward pricing pressures on existing agents, the seven-country market for diabetic nephropathy drugs will remain flat. Diabetes-related cardiovascular disease -- Approximately 30% of cardiovascular disease (CVD) in the United States is due to diabetes. The lipid-lowering strategy for treating atherosclerosis and decreasing the likelihood of ischemic events will continue to dominate the CVD market. The total seven-country market for lipid-lowering drugs is projected to reach $7.45 billion by 2005. For more information, visit the DR Reports web site at dresources.com Jounalists contact: Cindy Corona, Phone 781-487-3721, E-mail corona@dresources.com Sales inquiries, contact: Jean Carbone, Phone 781-487-3737, E-mail drreports@dresources.com. This report is available for $3500.00. DR Reports analyze technological advances, regulatory developments, and business trends in the health care industry. Decision Resources was founded as a subsidiary of Arthur D. Little, Inc., and is now an independent, employee-owned health care research and consulting firm. SOURCE Decision Resources CO: Decision Resources ST: Massachusetts IN: MTC SU: 11/10/98 10:16 EST prnewswire.c